Newron Pharmaceuticals: Commercialization partner Zambon together with Valeo Pharma announce the approval of Onstryv® (safinamide) for Parkinson’s disease in Canada
You are currently viewing a placeholder content from Elfsight. To access the actual content, click the button below. Please note that doing so will share data with third-party providers.
